Alkem Laboratories saw its net profit fall to ₹675 crore for the second quarter ended September 30. While total revenue rose to ₹4,552 crore, biotech sales fell 35 per cent. Managing Director Sandeep Singh said the company saw "continued momentum in the India business, supported by focused execution across our portfolios."
The company posted total revenue from operations at ₹4,552 crore, up 13.8% compared to the same period last year
Alkem Laboratories saw a drop in its consolidated net profit of close to 12 per cent at ₹675 crore, for the second quarter ended September 30, 2026.
The company posted total revenue from operations at ₹4,552 crore, up 13.8 per cent compared to the same period last year. But its biotech sales at ₹70 crore, saw a 35 per cent degrowth in the quarter under review, due to the "lumpy" nature of the CDMO (contract development and manufacturing organization) business, Alkem Managing Director Sandeep Singh, told analysts.
The company's Q2 performance reflected "continued momentum in the India business, supported by focused execution across our acute and chronic portfolios," he said. "The international business delivered steady progress despite continued pricing pressure in the US, with volume growth providing support. .. we also expanded our MedTech presence through the addition of Occlutech, while improving execution and operating performance at Enzene remains a key priority," he added. Enzene is the biologicals arm of Alkem, and Singh said he was optimistic about the growth of Enzene and their med-tech business. The company has recently appointed Dr Amrut Naik as Chief Executive Officer.
The company's India sales, at ₹3,027 crore, saw a 9.5 per cent growth over the same period last year - accounting for over 60 per cent of its revenue. Its international sales stood at ₹1,454 crore, growing 22.3 percent over the same period last year. Its medtech sales at ₹133 crore (including Occlutech). Alkem's net cash stoot at ₹4,905 crore, as on 30 September 2026.
On the regulatory front, he said, remediation efforts were underway at their Daman facility, to address the US Food and Drug Administration's OAI (Official Action Indicated) observation. The USFDA observation at their Mandva active pharmaceutical ingredients facility concluded with not Form 483 observations, he added.